AU Patent

AU2016301282B2 — Charged ion channel blockers and methods for use

Assigned to Boston Childrens Hospital · Expires 2022-03-17 · 4y expired

What this patent protects

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

USPTO Abstract

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: AU2016301282B2
Jurisdiction: AU
Classification: —
Expires: 2022-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Boston Childrens Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.